Drugmaker Cipla has posted a net profit of ₹343 crore for the quarter ended December 31, 2015, against ₹327 crore in the corresponding period the previous year.
The company’s total income stood at ₹3,185 crore for the three months under review, against ₹2,806 crore in the corresponding quarter last year.
The company said that its financial performance for the quarter included some of its subsidiaries from the date they became part of the company and so it could not be compared with its numbers in the same period last year.
Over 60 per cent of its sales came from the international markets and 95 per cent of revenues from its finished drugs business.
The company’s domestic sales in the quarter under review stood at ₹1,194 crore against ₹1,199 crore in the same period last year.
Export of its finished medicine clocked revenues of ₹ 1,833 crore in the period under review. Export of Active Pharmaceutical Ingredients, though, declined to ₹143 crore, the company said.